摘要
目的研究美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果。方法选取2010年3月至2017年6月在本院接受冠心病心力衰竭治疗的患者,其中住院患者2000例和门诊患者2500例,共计4500例患者作为研究对象,按照随机数字表法分成观察组和对照组,各2250例。对照组给予利尿剂、强心剂、血管紧张素转换酶抑制剂等药物进行常规治疗;观察组在对照组基础上再给予酒石酸美托洛尔片和盐酸曲美他嗪片治疗,治疗3个月,观察比较两组患者临床治疗效果、生命体征、心功能和炎症因子变化情况。结果治疗后,观察组临床治疗总有效率为91.82%,明显高于对照组的79.69%(P<0.05);两组HR、SBP、DB、LVEDD、LVESD、NT-pro BNP、IL-6、TNF-α和hs-CRP均较治疗前显著降低,且观察组均显著低于对照组(P<0.05);两组LVEF均升高,且观察组明显高于对照组(P<0.05)。结论对冠心病心力衰竭患者使用美托洛尔联合曲美他嗪进行治疗,临床效果好,能够显著改善患者生命体征和心功能,降低炎症反应和心肌重构风险。
bObjective To study the clinical effct of metoprolol combined with trimetazidine in the treatment of patients with coronary heart disease and heart failure. Methods A total of 4500 patients who received coronary heart disease and heart failure treatment in our hospital between March 2010 and June 2017 were selected. Among them,2,000 were hospitalized and2,500 were outpatients. Using the random number table method,these patients were evenly divided into the observation group and control group. The control group was treated with such drugs as diuretics,cardiac stimulants and angiotensin converting enzyme inhibitors. The observation group was additionally given metoprolol tablets and trimetazidine hydrochloride tablets. After 3 months of treatment,the therapeutic effect,vital signs,cardiac function and inflammatory factors were compared between the two groups. Results After treatment,the total effective rate in the observation group was 91. 82%,which was significantly higher than 79. 69% in the control group of（ P〈0. 05）. Levels of HR、SBP、DB、LVEDD、LVESD、NT-pro BNP、IL-6、TNF-αand hs-CRP were significantly lower in both groups after treatment,especially in the observation group（ P〈0. 05）. LVEF was elevated in both groups,especially in the observation group（ P〈0. 05）. Conclusion The clinical effect of treating patients with coronary heart disease and heart failure with metoprolol combined trimetazidine is good,which can significantly improve the patients＇ vital signs and cardiac function while reducing the risk of inflammation and myocardial remodeling.
作者
刘廷怡
刘瑶
王安伟
LIU Tingyi;LIU Yao;WANG Anwei(Department of Cardiology,Chongzhou People＇s Hospital,Zigong Sichuan,611230,China)
出处
《解放军预防医学杂志》
CAS
2018年第6期713-716,共4页
Journal of Preventive Medicine of Chinese People's Liberation Army
关键词
美托洛尔
曲美他嗪
冠心病
心力衰竭
metoprolol
trimetazidine
coronary heart disease
heart failure
